Powered by

Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia; -- Research Collaboration will Leverage HiFiBiO's Proprietary Single-Cell Platform to Identify Novel Targets to Support Kite's Development of Ce

Sep 03, 2020 - Business Wire
Partnership Announcement

Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML). Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite's use in cell therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2020090300516...